Loading...
OTCM
BSEM
Market cap204mUSD
Jul 11, Last price  
12.52USD
1D
0.59%
1Q
-2.99%
Jan 2017
24.62%
IPO
-100.00%
Name

Biostem Technologies Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
12.26
EPS
Div Yield, %
Shrs. gr., 5y
11.08%
Rev. gr., 5y
74.98%
Revenues
17m
+142.69%
1,262,3801,363,500806,74015,30931,193151,536592,297328,5281,017,1922,630,3182,521,6394,340,8396,875,20216,685,405
Net income
-8m
L+19.90%
-238,277-527,137-3,332,281-441,780-205,597-2,380,450-3,562,811-4,841,407-7,594,973-6,383,601-2,389,232-1,445,383-7,074,861-8,482,984
CFO
-3m
L+113.75%
-71,831-273,851-642,567-277,786-97,805-353,576-1,638,741-1,885,050-3,660,417-845,795-581,566-109,439-1,636,943-3,498,960
Earnings
Aug 11, 2025

Profile

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
IPO date
Jul 11, 2001
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
16,685
142.69%
6,875
58.38%
Cost of revenue
23,515
11,530
Unusual Expense (Income)
NOPBT
(6,829)
(4,655)
NOPBT Margin
Operating Taxes
430
Tax Rate
NOPAT
(6,829)
(5,085)
Net income
(8,483)
19.90%
(7,075)
389.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,380
50
BB yield
-2.96%
-0.15%
Debt
Debt current
4,490
4,051
Long-term debt
347
1,058
Deferred revenue
(111)
Other long-term liabilities
51
Net debt
4,598
4,337
Cash flow
Cash from operating activities
(3,499)
(1,637)
CAPEX
(105)
(469)
Cash from investing activities
(210)
(469)
Cash from financing activities
3,177
573
FCF
(8,845)
(6,965)
Balance
Cash
239
772
Long term investments
Excess cash
428
Stockholders' equity
(45,608)
(36,884)
Invested Capital
49,038
37,963
ROIC
ROCE
EV
Common stock shares outstanding
13,707
11,405
Price
5.86
95.99%
2.99
187.50%
Market cap
80,323
135.54%
34,102
180.61%
EV
84,921
38,566
EBITDA
(6,434)
(4,411)
EV/EBITDA
Interest
468
Interest/NOPBT